ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Genzyme, Voyager In Gene Therapy Pact

by Lisa M. Jarvis
February 16, 2015 | APPEARED IN VOLUME 93, ISSUE 7

Genzyme, the rare disease arm of Sanofi, is paying Voyager Therapeutics $65 million up front as part of a pact to develop gene therapies for central nervous system disorders, including Parkinson’s disease, Friedreich’s ataxia, and Huntington’s disease. Genzyme, which gains an option to license multiple programs after proof-of-concept human studies, is also taking a stake worth $35 million in the Cambridge, Mass.-based biotech firm. Separately, Sanofi has eliminated about 100 R&D positions at its Boston research labs. The company calls the move a “natural evolution of its R&D organization.”

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment